Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

INTS

Intensity Therapeutics Inc

4.84

Jul 14 • 12:15PM ET -0.09 (-1.73%)

Healthcare Biotechnology USA Nano NASD

Peers: BLRX CYCN ERNA GDTC GNTA GTBP ICU MBRX RKTO TOVX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	13.07M
Enterprise Value	2.93M
Income	-10.69M
Sales	0.00M
Book/sh	3.93
Cash/sh	3.79
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Jun 30, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.23
P/C	1.28
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.86
Current Ratio	4.86
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-7.08
EPS next Y	-3.40
EPS next Q	-0.87
EPS this Y	59.61%
EPS next Y	1.76%
EPS next 5Y	16.24%
EPS past 3/5Y	16.06% 5.76%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.15%
Sales Y/Y TTM	-
EPS Q/Q	82.58%
Sales Q/Q	-
Earnings	May 07 AMC
EPS/Sales Surpr.	11.52% -

Insider Own	4.73%
Insider Trans	0.00%
Inst Own	6.08%
Inst Trans	-0.11%
ROA	-139.27%
ROE	-207.37%
ROIC	-106.41%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.97%
SMA50	9.43%
SMA200	-35.74%
Trades

Shs Outstand	2.70M
Shs Float	2.57M
Short Float	4.92%
Short Ratio	2.96
Short Interest	0.13M
52W High	43.50 -88.89%
52W Low	3.51 37.75%
Volatility	5.74% 5.75%
ATR (14)	0.24
RSI (14)	65.00
Beta	2.99
Rel Volume	0.75
Avg Volume	42.65K
Volume	14,570

Perf Week	1.15%
Perf Month	31.74%
Perf Quarter	-11.45%
Perf Half Y	-53.45%
Perf YTD	-52.85%
Perf Year	-42.27%
Perf 3Y	-96.60%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	23.50
Prev Close	4.92
Price	4.84
Change	-1.73%

Jul-01-26 08:00AM	Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 (PR Newswire)
May-14-26 08:00AM	Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award (PR Newswire)
May-07-26 04:06PM	Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Apr-15-26 09:15AM	Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation (PR Newswire)
Mar-27-26 04:12PM	Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update (PR Newswire) -5.80%
08:00AM	Loading…
Mar-24-26 08:00AM	Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US (PR Newswire)
Mar-12-26 07:30AM	Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study (PR Newswire) -6.19%
Mar-06-26 07:47AM	Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement (PR Newswire)
Feb-13-26 12:28PM	What's Going On With Intensity Therapeutics Stock Friday? (Benzinga) -32.58%
08:58AM	Intensity Therapeutics Announces Reverse Stock Split (PR Newswire)
Jan-13-26 07:47AM	Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities (PR Newswire)
Dec-15-25 12:00PM	All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy (Zacks) -9.74%
Dec-11-25 07:47AM	Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium (PR Newswire) +7.27%
Dec-05-25 07:30AM	Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement (PR Newswire) +10.80%
Dec-04-25 07:47AM	Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium (PR Newswire) +12.32%
04:02PM	Loading…
Nov-06-25 04:02PM	Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) -14.86% -6.22%
Oct-31-25 08:19AM	Intensity Therapeutics stock up nearly 400% on solid tumour data (Clinical Trials Arena) -44.68%
08:00AM	Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock (PR Newswire)
Oct-30-25 07:30AM	Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal (PR Newswire) +394.57%
Sep-10-25 07:47AM	Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update (PR Newswire) -9.57%
Sep-02-25 07:47AM	Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-12-25 07:47AM	Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement (PR Newswire) +8.81%
Aug-07-25 04:06PM	Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) -7.59% +7.10%
Aug-04-25 07:47AM	Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 (PR Newswire) +11.13%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
08:00AM	Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) (PR Newswire)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -13.17%
Jun-11-25 11:46PM	Intensity Therapeutics, Inc. Announces Pricing of Public Offering (PR Newswire) +15.11% -44.73%
04:06PM	Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
08:30AM	Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study (PR Newswire)
08:00AM	Loading…
May-29-25 08:00AM	Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (PR Newswire) +24.00%
May-28-25 08:00AM	Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon (PR Newswire)
May-13-25 04:06PM	Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) -7.03%
May-06-25 08:00AM	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France (PR Newswire)
Apr-25-25 08:00AM	Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering (PR Newswire) -37.14%
Apr-21-25 09:40AM	Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-03-25 09:40AM	Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? (Zacks)
Mar-13-25 04:07PM	Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update (PR Newswire)
Jan-28-25 08:00AM	Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') Following Periodic Review (PR Newswire)
Jan-10-25 08:00AM	Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 (PR Newswire) +8.47%
Dec-13-24 08:10AM	Intensity Therapeutics reports positive results of INT230-6 in breast cancer (TipRanks)
Dec-12-24 08:00AM	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS) (PR Newswire) -12.14%
Nov-21-24 08:00AM	Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire) -8.47%
Nov-18-24 08:00AM	Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ('INVINCIBLE-3 Study') in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS) (PR Newswire)
Nov-13-24 04:06PM	Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) -8.55%
Nov-08-24 08:01AM	Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting (PR Newswire)
Oct-31-24 09:00AM	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) (PR Newswire) +6.56%
Sep-04-24 08:00AM	Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-08-24 04:19PM	Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-09-24 08:01AM	Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma (PR Newswire)
May-15-24 08:01AM	Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors (PR Newswire) +9.28%
May-10-24 10:48AM	Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial (MT Newswires) +6.38%
08:01AM	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate (PR Newswire)
May-09-24 11:54PM	INTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024 (InvestorPlace)
04:08PM	Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Apr-02-24 08:01AM	Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024 (PR Newswire) -7.82%
Mar-26-24 11:53PM	INTS Stock Earnings: Intensity Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.25%
08:01AM	Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares (GlobeNewswire)
Mar-14-24 04:09PM	Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +15.62%
08:00AM	Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024 (PR Newswire)
Feb-21-24 08:01AM	Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference (PR Newswire)
Jan-03-24 08:01AM	Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program (PR Newswire) -7.84%
Dec-12-23 08:01AM	Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer (PR Newswire)
Dec-08-23 11:12AM	Why Is Intensity Therapeutics (INTS) Stock Up 133% Today? (InvestorPlace) +72.00%
08:30AM	Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS (PR Newswire)
Dec-01-23 08:01AM	Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium (PR Newswire) +28.55%
Nov-13-23 08:01AM	Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update (PR Newswire)
Nov-02-23 07:01AM	Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023 (PR Newswire)
Sep-07-23 08:01AM	Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma (PR Newswire)
Sep-05-23 08:01AM	Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 07:01AM	Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-23 07:01AM	Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update (PR Newswire)
Jul-31-23 04:05PM	Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update (GlobeNewswire) +5.14%
Jul-10-23 08:00AM	Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds (PR Newswire)
Jul-05-23 04:15PM	Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds (PR Newswire)
Jun-29-23 08:00PM	Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds (PR Newswire)

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

M.B.A.Mr. Lewis H. Bender M.A.

M.B.A.Mr. Joseph Talamo CPA

M.B.A.Mr. John Wesolowski CPA

Executive Vice President of Corporate FinanceMr. James M. Ahlers

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INTS

Intensity Therapeutics Inc

Upgrade your Finviz experience